



RLS GLOBAL

Gentle Methods

ChloraSolv shows notably greater antibiofilm activity *in vitro* compared to other debridement products in published article

A recently published article in Wounds UK concludes that ChloraSolv wound debridement gel shows notably greater antibiofilm activity *in vitro*, compared to other debridement products and techniques, thus highlighting the promise for ChloraSolv which combines softening of devitalised tissue with antibiofilm activity.

The peer-reviewed article “The *in vitro* antibiofilm performance of ChloraSolv® Wound Debridement Gel” (authors Dr Daniel Metcalf, Dr Kate Meredith and Susanne Olausson) was recently published in the journal Wounds UK, Vol 19, No 1, 2023. The article [is available here](#).

The article concludes that ChloraSolv showed notably greater antibiofilm activity compared to other debridement techniques/products. Although this study only examined the *in vitro* antibiofilm activity of ChloraSolv, in conjunction with recent clinical studies which focused on easier debridement of devitalised tissue, it highlights the promise for this new wound debridement gel which combines tissue softening and antibiofilm activity.

“We are pleased to see the conclusions from the article, specifically on the superior antibiofilm activity of ChloraSolv compared with other wound debridement techniques/products available to healthcare professionals. The results further strengthens the evidence that ChloraSolv enables convenient, effective and gentle debridement by combining the softening of devitalised tissue with antibiofilm activity”, says Björn Larsson, CEO, RLS Global.

TRADING PLACE AND CERTIFIED ADVISER:

RLS Global's shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

FOR MORE INFORMATION, PLEASE CONTACT:

Björn Larsson, CEO, RLS Global
E-mail: bjorn.larsson@rlsglobal.se
Tel: +46 766 20 17 25

ABOUT RLS GLOBAL:

RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.

RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand into new indications through new research and development projects in areas such as wound care and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at rls.global